Design and rationale of FLAVOUR: A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarction
Eva Prescott, John Pernow, Antti Saraste, Axel Åkerblom, Oskar Angerås, David Erlinge, Erik L Grove, Marja Hedman, Lisette O Jensen, Sara Svedlund, Magnus Kjaer, Maria Lagerström-Fermér, Li-Ming Gan
Dyk ned i forskningsemnerne om 'Design and rationale of FLAVOUR: A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarction'. Sammen danner de et unikt fingeraftryk.